iSAM Funds UK Ltd Invests $1.47 Million in Boston Scientific Corporation $BSX

Key Points

• iSAM Funds UK Ltd purchased a new stake of 15,079 shares in Boston Scientific during Q3, valued at approximately $1.47 million.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 for about $15.04 million, a 10.23% decrease in his ownership.
• Boston Scientific is facing a shareholder class action alleging misrepresentation of electrophysiology volumes and several analysts have cut price targets, though the consensus rating remains Moderate Buy with an average target of $108.00.

iSAM Funds UK Ltd purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,079 shares of the medical equipment provider's stock, valued at approximately $1,472,000.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. State Street Corp boosted its position in shares of Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Synergy Asset Management LLC grew its stake in shares of Boston Scientific by 3,493.0% during the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider's stock worth $48,297,000 after purchasing an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC increased its holdings in Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider's stock valued at $5,065,000 after purchasing an additional 14,700 shares during the last quarter. Finally, Channel Wealth LLC increased its holdings in Boston Scientific by 70.8% in the third quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider's stock valued at $2,790,000 after purchasing an additional 11,847 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Saturday. Oppenheimer lowered their price target on Boston Scientific from $125.00 to $100.00 and set an "outperform" rating for the company in a research note on Friday, January 16th. Citigroup cut their price target on shares of Boston Scientific from $102.00 to $94.00 and set a "buy" rating on the stock in a research report on Wednesday. Canaccord Genuity Group reduced their price objective on shares of Boston Scientific from $112.00 to $109.00 and set a "buy" rating on the stock in a research note on Tuesday, February 17th. Finally, Needham & Company LLC decreased their price objective on shares of Boston Scientific from $121.00 to $97.00 and set a "buy" rating for the company in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $108.00.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.50% of the company's stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Stock Up 0.9%

Shares of Boston Scientific stock opened at $69.15 on Friday. The company has a market capitalization of $102.61 billion, a P/E ratio of 35.64, a price-to-earnings-growth ratio of 0.96 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The business has a 50-day moving average of $82.47 and a two-hundred day moving average of $93.39. Boston Scientific Corporation has a 1 year low of $67.56 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analysts' expectations of $5.29 billion. During the same quarter in the previous year, the business posted $0.70 EPS. Boston Scientific's revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.